All News
Filter News
Found 808,921 articles
-
Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
4/28/2021
Findings from a Phase 1 single ascending dose trial indicate the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis (OA), was generally well-tolerated Two of five patients (40%) treated with FX201 in the low-dose, single ascending dose cohort reported substantial improvement in pain out to Week 24 No evidence of systemic biodistribution of FX201 in plasma or shedding in urine or at the injection site was observed in any patient
-
Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit
4/28/2021
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7th Annual Truist Securities Life Sciences Summit
-
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
4/28/2021
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences:
-
Innoviva Reports First Quarter 2021 Financial Results
4/28/2021
Innoviva, Inc. (NASDAQ:INVA) (“Innoviva” and “the Company”) today reported financial results for the first quarter ended March 31, 2021.
-
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
4/28/2021
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the upcoming presentation of preclinical proof-of-concept data for OTO-825 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 13, 2021.
-
Biohaven to Report First Quarter 2021 Financial Results and Recent Business Developments on May 10, 2021
4/28/2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming first quarter 2021 earnings call and webcast, reporting financial results
-
Quanterix Corporation to Release First Quarter 2021 Financial Results on May 5, 2021
4/28/2021
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for first quarter 2021 after the close of trading on Wednesday, May 5, 2021
-
CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation
4/28/2021
CorWave, a French medical device company committed to the fight against heart failure, unveiled an unprecedented study on the performance of its implantable heart pump at the 41st Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT).
-
Soligenix Presents at the National Foundation for Infectious Diseases Annual Conference on Vaccinology Research
4/28/2021
Soligenix, Inc. announced today that its Senior Vice President and Chief Scientific Officer, Oreola Donini, PhD, delivered a presentation demonstrating the potency of the CiVax™ (COVID-19 vaccine) development program in mice and non-human primates (NHPs), at the Annual Conference on Vaccinology Research (ACVR) on April 26-27, 2021.
-
Stealth BioTherapeutics Announces Poster Presentation at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
4/28/2021
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
-
DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021
4/28/2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesday, May 5th
-
Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update
4/28/2021
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on Wednesday, May 5 , 2021. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time )
-
Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
4/28/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2021 financial results and provide a corporate update on Wednesday, May 5, 2021, after the close of the U.S. financial markets.
-
Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2021 ASCO Annual Meeting
4/28/2021
Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced an abstract has been accepted for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting which will be held virtually from June 4-8, 2021.
-
Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
4/28/2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its first quarter 2021 financial results will be released after the market closes on Wednesday, May 5, 2021.
-
Hologic Announces Financial Results for Second Quarter of Fiscal 2021
4/28/2021
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 27, 2021.
-
Amicus Therapeutics Recognized as a Great Place to Work® in EuropeGreat Place to Work® Certification in the United Kingdom, Spain, Italy and Germany
4/28/2021
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been recognized by the prestigious Great Place to Work® Institute as among the best places to work in the United Kingdom, Spain, Italy and Germany.
-
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
4/28/2021
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021
-
Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
4/28/2021
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2021,
-
Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021
4/28/2021
-- Conference Call Scheduled for Monday, May 3, 2021, at 8:30 a.m. ET --